{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:52:27Z","timestamp":1791910347479,"version":"4.3.4"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bcp.2026.118268","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:53:23Z","timestamp":1784303603000},"page":"118268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Advanced therapy medicinal products for local treatment using new delivery methods"],"prefix":"10.1016","volume":"253","author":[{"given":"Marcin","family":"Zaradzki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin P.","family":"Soethoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca Kliesow","family":"Remes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver J.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2723-5953","authenticated-orcid":false,"given":"Andreas H.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict","family":"Morath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118268_b0005","unstructured":"European Medicines Agency, Glybera: EPAR \u2013 Product Information, 2012. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/glybera."},{"key":"10.1016\/j.bcp.2026.118268_b0010","year":"2009","journal-title":"Information"},{"key":"10.1016\/j.bcp.2026.118268_b0015","unstructured":"European Medicines Agency, Public Statement on ChondroCelect: Withdrawal of the Marketing Authorisation in the European Union., 2016. https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/public-statement-chondrocelect-withdrawal-marketing-authorisation-european-union_en.pdf. (Accessed 17 March 2026."},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1208\/s12249-024-03010-6","article-title":"Gene therapy: towards a new era of medicine","volume":"26","author":"Bhagat","year":"2024","journal-title":"AAPS PharmSciTech"},{"issue":"7","key":"10.1016\/j.bcp.2026.118268_b0025","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41431-020-0607-y","article-title":"Gene therapy regulation: could in-body editing fall through the net?","volume":"28","author":"Mourby","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.bcp.2026.118268_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.hlpt.2023.100744","article-title":"Unlocking the value of innovative medicines: Insights from the advanced therapy medicinal products (ATMP) innovation systems in Germany and Sweden","volume":"12","author":"Fischer","year":"2023","journal-title":"Health Policy Technol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118268_b0035","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","article-title":"Population pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Dirks","year":"2010","journal-title":"Clin. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.bcp.2026.118268_b0040","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118268_b0045","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1345\/aph.1D374","article-title":"Population pharmacokinetics I: background, concepts, and models","volume":"38","author":"Ette","year":"2004","journal-title":"Ann. Pharmacother."},{"issue":"9","key":"10.1016\/j.bcp.2026.118268_b0050","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/bcp.14281","article-title":"Chimeric antigen receptor T-cell therapies: Optimising the dose","volume":"86","author":"Dasyam","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118268_b0055","unstructured":"European Union, Regulation (EC) No 1394\/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001\/83\/EC and Regulation (EC) No 726\/2004, Publications Office of the European Union, Luxembourg, 2007, pp. 121\u2013137."},{"issue":"9","key":"10.1016\/j.bcp.2026.118268_b0060","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40263-022-00941-1","article-title":"Onasemnogene abeparvovec: a review in spinal muscular atrophy","volume":"36","author":"Blair","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bcp.2026.118268_b0065","unstructured":"European Union, Directive 2009\/120\/EC amending Directive 2001\/83\/EC, 2009. https:\/\/eur-lex.europa.eu\/eli\/dir\/2009\/120\/oj\/eng. (Accessed 07 July 2026."},{"key":"10.1016\/j.bcp.2026.118268_b0070","unstructured":"European Medicines Agency, Advanced therapy medicinal products: overview, 2006. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/advanced-therapy-medicinal-products-overview. (Accessed 17 March 2026 2006)."},{"key":"10.1016\/j.bcp.2026.118268_b0075","unstructured":"European Medicines Agency, Ebvallo \u2013 Tabelecleucel: European Public Assessment Report (EPAR), 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ebvallo (Accessed 07 July 2026."},{"issue":"1_suppl","key":"10.1016\/j.bcp.2026.118268_b0080","doi-asserted-by":"crossref","first-page":"1195s","DOI":"10.1177\/1947603520968884","article-title":"Scientific developments and clinical applications utilizing chondrons and chondrocytes with matrix for cartilage repair","volume":"13","author":"Shah","year":"2021","journal-title":"Cartilage"},{"issue":"11","key":"10.1016\/j.bcp.2026.118268_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115224","article-title":"Neutralizing antibodies: role in immune response and viral vector based gene therapy","volume":"26","author":"Tsaregorodtseva","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"13\u201314","key":"10.1016\/j.bcp.2026.118268_b0090","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1089\/hum.2023.162","article-title":"Circumventing B cell responses to allow for redosing of adeno-associated virus vectors","volume":"35","author":"Ertl","year":"2024","journal-title":"Hum. Gene Ther."},{"issue":"4","key":"10.1016\/j.bcp.2026.118268_b0095","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1089\/hum.2017.048","article-title":"AAV: an overview of unanswered questions","volume":"28","author":"Berns","year":"2017","journal-title":"Hum. Gene Ther."},{"issue":"4","key":"10.1016\/j.bcp.2026.118268_b0100","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of transgene expression after rAAV gene therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.bcp.2026.118268_b0105","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/JOM.0000000000000879","article-title":"Risks associated with lentiviral vector exposures and prevention strategies","volume":"58","author":"Schlimgen","year":"2016","journal-title":"J. Occup. Environ. Med."},{"issue":"5466","key":"10.1016\/j.bcp.2026.118268_b0110","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.118268_b0115","unstructured":"European Medicines Agency, Kymriah, INN-tisagenlecleucel: EPAR \u2014 Product information, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kymriah-epar-product-information_en.pdf. (Accessed 17 March 2026 17 March 2026)."},{"issue":"5","key":"10.1016\/j.bcp.2026.118268_b0120","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-023-00842-1","article-title":"PK\/PD and bioanalytical considerations of AAV-based gene therapies: an IQ consortium industry position paper","volume":"25","author":"Kavita","year":"2023","journal-title":"AAPS J."},{"key":"10.1016\/j.bcp.2026.118268_b0125","unstructured":"U.S. Food and Drug Administration, Package Insert - ZOLGENSMA (onasemnogene abeparvovec\u2011xioi), 2024. https:\/\/www.fda.gov\/media\/126109\/download. (Accessed 17 March 2026."},{"key":"10.1016\/j.bcp.2026.118268_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105597","article-title":"Computational modelling of CAR T-cell therapy: from cellular kinetics to patient-level predictions","volume":"113","author":"Murias-Closas","year":"2025","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118268_b0140","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bcp.2026.118268_b0145","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bcp.2026.118268_b0150","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40262-021-01039-5","article-title":"Population cellular kinetics of lisocabtagene maraleucel, an autologous CD19-directed chimeric antigen receptor T-cell product, in patients with relapsed\/refractory large B-cell lymphoma","volume":"60","author":"Ogasawara","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.bcp.2026.118268_b0155","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s40262-024-01413-z","article-title":"Investigating the influence of covariates on axicabtagene ciloleucel (axi-cel) kinetics in patients with non-hodgkin's lymphoma","volume":"63","author":"Chartier","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcp.2026.118268_b0160","unstructured":"European Medicines Agency, Upstaza (eladocagene exuparvovec) \u2014 EPAR Product Information EMA\/365735\/2022, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/upstaza-epar-product-information_en.pdf. (Accessed 17 March 2026."},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0165","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.70106","article-title":"Viral vector-based gene therapies in the clinic: an update","volume":"11","author":"Park","year":"2026","journal-title":"Bioeng. Transl. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118268_b0170","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.hlc.2023.02.011","article-title":"Barriers in Heart failure Gene Therapy and Approaches to Overcome Them","volume":"32","author":"Ravichandran","year":"2023","journal-title":"Heart Lung Circ."},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0175","article-title":"Non viral vectors in gene therapy- an overview","volume":"9","author":"Ramamoorth","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.118268_b0180","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"issue":"12","key":"10.1016\/j.bcp.2026.118268_b0185","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"7","key":"10.1016\/j.bcp.2026.118268_b0190","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41467-022-35637-z","article-title":"Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis","volume":"14","author":"Han","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2026.118268_b0200","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1021\/acs.chemrev.5b00346","article-title":"Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release","volume":"116","author":"Kamaly","year":"2016","journal-title":"Chem. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2026.118268_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/polym11040745","article-title":"Polymeric nanoparticles in gene therapy: new avenues of design and optimization for delivery applications","volume":"11","author":"Rai","year":"2019","journal-title":"Polymers (basel)"},{"issue":"7","key":"10.1016\/j.bcp.2026.118268_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072536","article-title":"Nanoparticles modified with cell-penetrating peptides: conjugation mechanisms, physicochemical properties, and application in cancer diagnosis and therapy","volume":"21","author":"Gessner","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.bcp.2026.118268_b0215","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29143339","article-title":"Cell-penetrating peptide-mediated biomolecule transportation in artificial lipid vesicles and living cells","volume":"29","author":"Miwa","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2026.118268_b0220","article-title":"Peptide-enabled targeted delivery systems for therapeutic applications","volume":"9","author":"Liu","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118268_b0225","doi-asserted-by":"crossref","DOI":"10.1038\/s43586-022-00104-y","article-title":"Nanodelivery of nucleic acids","volume":"2","author":"Mendes","year":"2022","journal-title":"Nat. Rev. Methods Primers"},{"issue":"11","key":"10.1016\/j.bcp.2026.118268_b0230","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/anie.200504277","article-title":"Colorimetric screening of DNA-binding molecules with gold nanoparticle probes","volume":"45","author":"Han","year":"2006","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"12","key":"10.1016\/j.bcp.2026.118268_b0235","doi-asserted-by":"crossref","DOI":"10.3390\/ph18121772","article-title":"Advances in Lipid-polymer hybrid nanoparticles: design strategies, functionalization, oncological and non-oncological clinical prospects","volume":"18","author":"Jacob","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1016\/j.bcp.2026.118268_b0240","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ymthe.2025.03.064","article-title":"AAV vector development, back to the future","volume":"33","author":"Suarez-Amaran","year":"2025","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0245","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.118268_b0250","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.bcp.2026.118268_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050785","article-title":"Various AAV serotypes and their applications in gene therapy: an overview","volume":"12","author":"Issa","year":"2023","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.bcp.2026.118268_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103610","article-title":"Treatment to cure: advancing AAV gene therapy manufacture","volume":"28","author":"Young","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2026.118268_b0265","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.988914","article-title":"Routes of administration for adeno-associated viruses carrying gene therapies for brain diseases","volume":"15","author":"Zhou","year":"2022","journal-title":"Front. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0270","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s13023-025-03893-z","article-title":"In vivo applications and toxicities of AAV-based gene therapies in rare diseases","volume":"20","author":"Zhao","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"issue":"6","key":"10.1016\/j.bcp.2026.118268_b0275","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/cpt.3230","article-title":"Clinical pharmacology perspective on development of adeno-associated virus vector-based retina gene therapy","volume":"115","author":"Ford","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.118268_b0280","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ymthe.2024.04.013","article-title":"Intrathecal gene therapy for neurologic disease in humans","volume":"32","author":"Flotte","year":"2024","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2026.118268_b0285","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41591-021-01664-4","article-title":"AAV gene therapy for tay-sachs disease","volume":"28","author":"Flotte","year":"2022","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.bcp.2026.118268_b0290","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa2307952","article-title":"Intrathecal gene therapy for giant axonal neuropathy","volume":"390","author":"Bharucha-Goebel","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118268_b0295","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.ymthe.2025.03.056","article-title":"Advances in AAV capsid engineering: Integrating rational design, directed evolution and machine learning","volume":"33","author":"Nisanov","year":"2025","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.118268_b0300","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1016\/j.ymthe.2025.04.027","article-title":"Identification of a robust promoter in mouse and human hepatocytes by in vivo biopanning of a barcoded AAV library","volume":"33","author":"Becker","year":"2025","journal-title":"Mol. Ther."},{"issue":"10097","key":"10.1016\/j.bcp.2026.118268_b0305","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bcp.2026.118268_b0310","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.bcp.2026.118268_b0315","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years","volume":"128","author":"Maguire","year":"2021","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.bcp.2026.118268_b0320","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"issue":"10489","key":"10.1016\/j.bcp.2026.118268_b0325","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0140-6736(25)00717-2","article-title":"Gene therapy approval for Duchenne muscular dystrophy: a European perspective","volume":"405","author":"Jolly","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118268_b0330","unstructured":"U.S. Food and Drug Administration, FDA Approves New Safety Warning and Revised Indication that Limits Use for Elevidys Following Reports of Fatal Liver Injury, 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal. 17 March 2026)."},{"issue":"2","key":"10.1016\/j.bcp.2026.118268_b0335","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","article-title":"Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency","volume":"30","author":"Tai","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2026.118268_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2026.106294","article-title":"Progress and challenges in intrathecal gene therapy for neurological disorders","volume":"128","author":"Kagiava","year":"2026","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2026.118268_b0345","doi-asserted-by":"crossref","DOI":"10.1038\/s41434-026-00595-4","article-title":"AAV-based gene therapies for neovascular AMD","author":"Kim","year":"2026","journal-title":"Gene Ther."},{"key":"10.1016\/j.bcp.2026.118268_b0350","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.796991","article-title":"HEK293 Cell Line as a Platform to produce Recombinant Proteins and Viral Vectors","volume":"9","author":"Tan","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118268_b0355","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1002\/bit.28412","article-title":"Critical challenges and advances in recombinant adeno-associated virus (rAAV) biomanufacturing","volume":"120","author":"Fu","year":"2023","journal-title":"Biotechnol. Bioeng."},{"issue":"3","key":"10.1016\/j.bcp.2026.118268_b0360","first-page":"169","article-title":"A clinician's guide to AAV production- how manufacturing platforms shape vector properties","volume":"37","author":"Magnus","year":"2025","journal-title":"Med. Genet."},{"issue":"4","key":"10.1016\/j.bcp.2026.118268_b0365","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-Associated Virus (AAV) as a Vector for Gene Therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.bcp.2026.118268_b0370","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1089\/hum.2013.184","article-title":"OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy","volume":"25","author":"Mietzsch","year":"2014","journal-title":"Hum. Gene Ther."},{"issue":"13","key":"10.1016\/j.bcp.2026.118268_b0375","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1073\/pnas.0810614106","article-title":"An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells","volume":"106","author":"Aslanidi","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.bcp.2026.118268_b0380","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1089\/hum.2010.250","article-title":"Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02- to 200-liter cultures","volume":"22","author":"Cecchini","year":"2011","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0385","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/biomedicines2010080","article-title":"Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment","volume":"2","author":"Wright","year":"2014","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.bcp.2026.118268_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101503","article-title":"Residual DNA impurities in AAV vectors-nature and transcription","volume":"33","author":"Jen","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.bcp.2026.118268_b0395","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.omtm.2018.01.002","article-title":"Pharmacology of Recombinant Adeno-associated Virus Production","volume":"8","author":"Penaud-Budloo","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.bcp.2026.118268_b0400","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2019.12.008","article-title":"Immune Response Mechanisms against AAV Vectors in Animal Models","volume":"17","author":"Martino","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"580","key":"10.1016\/j.bcp.2026.118268_b0405","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.bcp.2026.118268_b0410","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","article-title":"A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders","volume":"32","author":"Vrellaku","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2026.118268_b0415","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.copbio.2019.01.002","article-title":"Engineering the AAV capsid to evade immune responses","volume":"60","author":"Barnes","year":"2019","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118268_b0420","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.672449","article-title":"Effect of CpG depletion of vector genome on CD8(+) T cell responses in AAV gene therapy","volume":"12","author":"Bertolini","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118268_b0425","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.bcp.2026.118268_b0430","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/mt.2013.166","article-title":"Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes","volume":"21","author":"Hui","year":"2013","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0435","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2026.118268_b0440","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/humc.2017.146","article-title":"Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by pompe disease","volume":"28","author":"Corti","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.bcp.2026.118268_b0445","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fimmu.2014.00082","article-title":"Immune responses to AAV-vectors, the glybera example from bench to bedside","volume":"5","author":"Ferreira","year":"2014","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118268_b0450","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","article-title":"Immunogenicity of recombinant adeno-associated virus (AAV) vectors for gene transfer","volume":"37","author":"Arjomandnejad","year":"2023","journal-title":"BioDrugs"},{"issue":"8","key":"10.1016\/j.bcp.2026.118268_b0455","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: an integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.bcp.2026.118268_b0460","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.bcp.2026.118268_b0465","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.bcp.2026.118268_b0470","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ymthe.2020.12.028","article-title":"Increasing the specificity of AAV-based gene editing through self-targeting and short-promoter strategies","volume":"29","author":"Breton","year":"2021","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2026.118268_b0475","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/gt.2010.141","article-title":"microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors","volume":"18","author":"Geisler","year":"2011","journal-title":"Gene Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.118268_b0480","article-title":"AAV vectors for specific and efficient gene expression in microglia","volume":"5","author":"Aoki","year":"2025","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.bcp.2026.118268_b0485","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.omtm.2021.02.017","article-title":"Alginate hydrogel polymers enable efficient delivery of a vascular-targeted AAV vector into aortic tissue","volume":"21","author":"Remes","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"6","key":"10.1016\/j.bcp.2026.118268_b0490","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.ymthe.2025.04.045","article-title":"Current clinical applications of AAV-mediated gene therapy","volume":"33","author":"Byrne","year":"2025","journal-title":"Mol. Ther."},{"issue":"15","key":"10.1016\/j.bcp.2026.118268_b0495","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1093\/cvr\/cvab370","article-title":"Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC working group on cellular biology of the heart","volume":"118","author":"van der Velden","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2026.118268_b0500","article-title":"Cardiac tissue engineering for translational cardiology: from in vitro models to regenerative therapies","volume":"12","author":"Jabri","year":"2025","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/j.bcp.2026.118268_b0505","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.reth.2025.06.017","article-title":"Current challenges and future directions of ATMPs in regenerative medicine","volume":"30","author":"Kakroodi","year":"2025","journal-title":"Regen Ther"},{"issue":"5","key":"10.1016\/j.bcp.2026.118268_b0510","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jbiomech.2009.11.007","article-title":"Cells in 3D matrices under interstitial flow: effects of extracellular matrix alignment on cell shear stress and drag forces","volume":"43","author":"Pedersen","year":"2010","journal-title":"J. Biomech."},{"issue":"11","key":"10.1016\/j.bcp.2026.118268_b0515","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9111634","article-title":"Improvement of cell culture methods for the successful generation of human keratinocyte primary cell cultures using EGF-loaded nanostructured lipid carriers","volume":"9","author":"Chato-Astrain","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0520","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13287-024-03790-5","article-title":"Osteochondral organoids: current advances, applications, and upcoming challenges","volume":"15","author":"Faeed","year":"2024","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"10.1016\/j.bcp.2026.118268_b0525","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41416-019-0672-6","article-title":"Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery","volume":"122","author":"Powley","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2026.118268_b0530","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3390\/pr9030447","article-title":"Digital twins for tissue culture techniques\u2014concepts, expectations, and state of the art","volume":"9","author":"M\u00f6ller","year":"2021","journal-title":"Processes"},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0535","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12967-024-05986-y","article-title":"Heart-on-a-chip: a revolutionary organ-on-chip platform for cardiovascular disease modeling","volume":"23","author":"Liu","year":"2025","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118268_b0540","doi-asserted-by":"crossref","DOI":"10.1063\/5.0163363","article-title":"FRESH\u2122 3D bioprinted cardiac tissue, a bioengineered platform for in vitro pharmacology","volume":"7","author":"Finkel","year":"2023","journal-title":"APL Bioeng."},{"issue":"11","key":"10.1016\/j.bcp.2026.118268_b0545","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/bjs\/znac264","article-title":"Advanced therapy medicinal products in surgery","volume":"109","author":"Wigmore","year":"2022","journal-title":"Br. J. Surg."},{"issue":"2","key":"10.1016\/j.bcp.2026.118268_b0550","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJMoa0905955","article-title":"Limbal stem-cell therapy and long-term corneal regeneration","volume":"363","author":"Rama","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0555","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/sctm.17-0003","article-title":"Navigating market authorization: the path holoclar took to become the first stem cell product approved in the European Union","volume":"7","author":"Pellegrini","year":"2018","journal-title":"Stem Cells Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0560","article-title":"Safety and efficacy of matrix-associated autologous chondrocyte implantation with spheroids for patellofemoral or tibiofemoral defects: a 5-year follow-up of a phase 2, dose-confirmation trial","volume":"10","author":"Hoburg","year":"2022","journal-title":"Orthop. J. Sports Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118268_b0565","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40273-018-0737-z","article-title":"Autologous chondrocyte implantation with chondrosphere for treating articular cartilage defects in the knee: an evidence review group perspective of a nice single technology appraisal","volume":"37","author":"Armoiry","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"10.1016\/j.bcp.2026.118268_b0570","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/DCR.0000000000002567","article-title":"A phase IB\/IIA study of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of perianal fistulizing crohn's disease","volume":"66","author":"Lightner","year":"2023","journal-title":"Dis. Colon Rectum"},{"issue":"8","key":"10.1016\/j.bcp.2026.118268_b0575","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14712598.2024.2383882","article-title":"The potential for medical therapies to address fistulizing Crohn's disease: a state-of-the-art review","volume":"24","author":"Shehab","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.118268_b0580","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/DCR.0000000000002325","article-title":"Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing crohn's disease: ADMIRE-CD phase 3 randomized controlled trial","volume":"65","author":"Garcia-Olmo","year":"2022","journal-title":"Dis. Colon Rectum"},{"issue":"4","key":"10.1016\/j.bcp.2026.118268_b0585","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/08164622.2021.1880863","article-title":"Gene therapy for inherited retinal diseases: progress and possibilities","volume":"104","author":"Hu","year":"2021","journal-title":"Clin. Exp. Optom."},{"issue":"3","key":"10.1016\/j.bcp.2026.118268_b0590","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/ICU.0000000000000660","article-title":"Gene therapy beyond luxturna: a new horizon of the treatment for inherited retinal disease","volume":"31","author":"Prado","year":"2020","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.bcp.2026.118268_b0595","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jconrel.2023.01.067","article-title":"AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges","volume":"355","author":"Kang","year":"2023","journal-title":"J. Control. Release"},{"issue":"19","key":"10.1016\/j.bcp.2026.118268_b0600","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1182\/bloodadvances.2023011847","article-title":"Roctavian gene therapy for hemophilia a","volume":"8","author":"Samelson-Jones","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.bcp.2026.118268_b0605","article-title":"A paradigm shift in hemophilia care: the promise of gene therapy","author":"Anver Pasha","year":"2025","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.bcp.2026.118268_b0610","unstructured":"European Medicines Agency, Vyjuvek \u2013 Beremagene geperpavec: European Public Assessment Report (EPAR), 2024 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vyjuvek (Accessed 07 July 2026."},{"issue":"17","key":"10.1016\/j.bcp.2026.118268_b0615","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1016\/j.cell.2023.07.031","article-title":"Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB)","volume":"186","author":"Epstein","year":"2023","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.bcp.2026.118268_b0620","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1097\/MS9.0000000000002146","article-title":"Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR\/Cas9 gene therapy for sickle cell disease","volume":"86","author":"Singh","year":"2024","journal-title":"Ann Med Surg (lond)"},{"key":"10.1016\/j.bcp.2026.118268_b0625","unstructured":"European Medicines Agency, Casgevy \u2013 Exagamglogene autotemcel: European Public Assessment Report (EPAR), 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/casgevy (Accessed 07 July 2026."},{"issue":"18","key":"10.1016\/j.bcp.2026.118268_b0630","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118268_b0635","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa2309149","article-title":"CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema","volume":"390","author":"Longhurst","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0640","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1186\/s12951-024-02965-9","article-title":"Targeted lipid nanoparticles distributed in hydrogel treat osteoarthritis by modulating cholesterol metabolism and promoting endogenous cartilage regeneration","volume":"22","author":"Zhao","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118268_b0645","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1208\/s12248-025-01155-1","article-title":"Physiologically based pharmacokinetic modeling and simulation in regulatory review: US FDA CBER experience and perspectives","volume":"27","author":"Tegenge","year":"2025","journal-title":"AAPS J."},{"key":"10.1016\/j.bcp.2026.118268_b0650","unstructured":"PragmaTIL, JOIN4ATMP: Leveraging PragmaTIL to Accelerate ATMP Development in Europe, 2025. https:\/\/pragmatil.eu\/2025\/01\/28\/join4atmp-pragmatil-accelerate-atmp-development-europe\/. (Accessed 18 March 2026."},{"key":"10.1016\/j.bcp.2026.118268_b0655","unstructured":"TU9 \u2013 German Universities of Technology, Outstanding Result for TU9 in the BMBF\u2019s \u201cClusters4Future\u201d Competition, 2021. https:\/\/www.tu9.de\/media\/download\/tu9-pm_clusters4future_21-02-04_en.pdf. (Accessed 4 February 2021 18 March 2026)."},{"issue":"8","key":"10.1016\/j.bcp.2026.118268_b0660","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118268_b0665","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"Elife"},{"issue":"9","key":"10.1016\/j.bcp.2026.118268_b0670","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using sleeping beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2026.118268_b0675","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.gde.2018.06.003","article-title":"Non-viral therapeutic cell engineering with the sleeping beauty transposon system","volume":"52","author":"Hudecek","year":"2018","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0680","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40164-024-00542-2","article-title":"Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers","volume":"13","author":"Gu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118268_b0685","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118268_b0690","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3389\/fimmu.2015.00578","article-title":"The application of natural killer cell immunotherapy for the treatment of cancer","volume":"6","author":"Rezvani","year":"2015","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0695","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","article-title":"NK cells and solid tumors: therapeutic potential and persisting obstacles","volume":"21","author":"Tong","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.118268_b0700","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"NPJ Regen Med"},{"issue":"6","key":"10.1016\/j.bcp.2026.118268_b0705","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"23","key":"10.1016\/j.bcp.2026.118268_b0710","first-page":"e91","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. reply","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118268_b0715","doi-asserted-by":"crossref","first-page":"7966","DOI":"10.1038\/s41467-022-35614-6","article-title":"Prediction of designer-recombinases for DNA editing with generative deep learning","volume":"13","author":"Schmitt","year":"2022","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.bcp.2026.118268_b0720","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/s41587-023-02121-y","article-title":"Activation of recombinases at specific DNA loci by zinc-finger domain insertions","volume":"42","author":"Mukhametzyanova","year":"2024","journal-title":"Nat. Biotechnol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:22:26Z","timestamp":1791908546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226006076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":144,"alternative-id":["S0006295226006076"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118268","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced therapy medicinal products for local treatment using new delivery methods","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118268"}}